Patents by Inventor Mark D. Peek

Mark D. Peek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR MODULATING HEPATOCYTE GROWTH FACTOR ACTIVATION
    Publication number: 20100209956
    Abstract: The invention provides methods and compositions for modulating hepsin activity and the HGF/c-met signaling pathway, in particular by regulating pro-HGF activation by hepsin.
    Type: Application
    Filed: March 10, 2010
    Publication date: August 19, 2010
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Paul M. Moran, Mark D. Peek
  • METHODS AND COMPOSITIONS FOR MODULATING HEPATOCYTE GROWTH FACTOR ACTIVATION
    Publication number: 20090075317
    Abstract: The invention provides methods and compositions for modulating hepsin activity and the HGF/c-met signaling pathway, in particular by regulating pro-HGF activation by hepsin.
    Type: Application
    Filed: August 29, 2008
    Publication date: March 19, 2009
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Paul M. Moran, Mark D. Peek
  • Methods and compositions for modulating hepatocyte growth factor activation
    Patent number: 7432044
    Abstract: The invention provides methods and compositions for modulating hepsin activity and the HGF/c-met signaling pathway, in particular by regulating pro-HGF activation by hepsin.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: October 7, 2008
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Paul M. Moran, Mark D. Peek
  • Hepatocyte growth factor variants
    Publication number: 20040138120
    Abstract: Serine proteases factor XIa and kallikrein cleave and activate HGF. Cleavage is at two sites: a typical cleavage site, Arg494-Val495, and a novel cleavage site, Arg424-His425. Variant HGF fragments obtained by cleaving at one or both of these sites may be useful as agonists or antagonists of HGF. Variants or fragments obtained by modifying these cleavage sites so as to be resistant to kallikrein and/or FXIa cleavage are also provided.
    Type: Application
    Filed: October 3, 2003
    Publication date: July 15, 2004
    Applicant: GENENTECH, INC.
    Inventors: Daniel K. Kirchhofer, Mark D. Peek